Several reports indicate that the use of Sig1R ligands to target therapeutic nanoparticles dramatically enhances the delivery of siRNA or drugs at the tumor site in melanoma, prostate, lung and breast cancer (Li and Huang, 2006; Chen et al., 2010; Guo et al., 2012; Kim and Huang, 2012). Here, SIGMAR1 is linked to neoplasm.